(Q44321908)

English

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar

scientific article published on 20 November 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Meindert Danhof

4

object named as

Meindert Danhof

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Frances Stringer

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Graham Scott

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

20 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

453-461

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Pharmacogenetics of Anti-Diabetes Drugs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Assessment of actual significance levels for covariate effects in NONMEM.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Extensions to the visual predictive check to facilitate model performance evaluation

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

A review of the response to oral antidiabetes agents in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

A simple way to estimate mean plasma glucose and to identify Type 2 diabetic subjects with poor glycaemic control when a standardized HbA1c assay is not available.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.227

21 January 2018

Identifiers

10.1002/JCPH.227

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44321908&oldid=2144180947"